Navigation Links
Epeius Biotechnologies to Partner at BIO Investor Forum
Date:10/20/2009

SAN FRANCISCO, Oct. 20 /PRNewswire/ -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco. Participating companies that are poised for leadership status in areas of therapeutic innovation are chosen through a competitive screening process, with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry.

The selection of Epeius Biotechnologies as an investment opportunity was based on the accomplishment of significant clinical development milestones with its lead oncology product, Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors by the Philippine FDA, and has recently received both Orphan Drug priorities and Fast Track designation by the U.S. FDA.

Epeius Biotechnologies is among a select group of companies which are recognized as those that are creating real value through development-stage programs with near-term clinical catalysts. According to the top-tier investor forum advisory committee, "These are the companies that will help drive the investment and deal making in the life sciences sector and global innovation in healthcare."

This prestigious forum provides an opportunity for senior management of Epeius Biotechnologies to showcase the remarkable clinical development of Rexin-G®, as stand-alone therapy for otherwise intractable metastatic cancers, and to partner with savvy investors that are capable of expediting the development of Rexin-G in the larger global market.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.

To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at http://www.epeiusbiotech.com .

*(LOGO 300dpi: www.Send2Press.com/mediaboom/09-1012-EpeiusBio_300dpi.jpg)

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com

SOURCE Epeius Biotechnologies


'/>"/>
SOURCE Epeius Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
2. Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
3. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
4. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
5. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo
8. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
9. Variation Biotechnologies Names Jeff Baxter CEO
10. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
11. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 2017 , ... AxioMed will be presenting its viscoelastic cervical ... Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the benefits ... the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... our ongoing endeavors to bring to market a pioneering medical device for the ... has signed an engagement contract with Emergo, a global regulatory consultancy that helps ...
(Date:1/21/2017)... BOULDER, Colo. , Jan. 20, 2017 ... ("Bioptix" or the "Company"), announced that on January 14, ... a plan under which the Company will terminate certain ... subsidiary, Bioptix Diagnostics, Inc.  The Company commenced terminations on ... completed within 30 days.  The Company may pay severance ...
Breaking Biology Technology:
(Date:1/11/2017)... 11, 2017 Intoxalock, a leading ignition interlock ... of its patent-pending calibration device. With this new technology, ... securely upload data logs and process repairs at service ... "Fighting drunk driving through the application of cutting-edge ... large, but also for the customer who can get ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its longstanding ... leading personal genetics company, recently released its latest children,s book, ... The book focuses on the topics of inheritance and variation ... Standards (NGSS) taught in elementary school classrooms in the US. ... series by illustrator Ariana Killoran , whose previous book ...
Breaking Biology News(10 mins):